secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOVIE INC. (BIVI)
CIK:        0001580149
Form:       8-K
Filed at:   2022-10-05T23:59:59+00:00
Accession:  0001520138-22-000448
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioVie reports 82% responder rate in Phase 2 Alzheimer's study; Phase 3 on track for mid-2023 readout
--------------------------------------------------------------------------------

- 82% of MCI/mild AD patients improved cognition (modified ADAS-Cog12) after 3 months; mean improvement -2.6 points (p=0.0046).
- Phase 3 NE3107 Alzheimer's trial has enrolled >50% of 316 patients; topline data expected mid-2023.
- Phase 2 Parkinson's NE3107 trial expected to read out by end of 2022; early blinded data consistent with animal studies.
- Phase 2b BIV201 ascites trial enrollment slowed by COVID; topline data now expected mid-2023.
- Full data from exploratory Alzheimer's study to be presented at CTAD conference Nov 29–Dec 2, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1580149/000152013822000448/0001520138-22-000448-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1580149/000152013822000448/bivi-20221004_8k.htm
  HTML page:      https://secwatch.observer/filing/0001520138-22-000448

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer